No Data
The Most Expensive Drug From Novartis Associated With Two Deaths: Report
Two children with spinal muscular atrophy have died after receiving Novartis AG's (NYSE:NVS) Zolgensma, a one-time gene therapy, spotlighting its risks and questioning the safety of genetic medicines
Novartis Says Two Children Treated With Gene-Therapy Zolgensma Died
By Maitane Sardon Novartis AG said that two children who received its gene therapy for a neuromuscular disease died after the treatment. The patients developed acute liver failure about five to six
Medicines and Healthcare products Regulatory Agency Grants Marketing Authorization for Novartis' Radioligand Therapy Pluvicto (Lutetium (¹⁷⁷lu) Vipivotide Tetraxetan) in Advanced Prostate Cancer in Great Britain
Medicines and Healthcare products Regulatory Agency Grants Marketing Authorization for Novartis' Radioligand Therapy Pluvicto (Lutetium (¹⁷⁷lu) Vipivotide Tetraxetan) in Advanced Prostate Cancer in Gr
Novartis says two children died after receiving gene therapy Zolgensma - STAT
Two children have died after receiving Novartis' (NYSE:NVS) spinal muscular atrophy gene therapy Zolgensma (onasemnogene abeparvovec), STAT reported. The deaths occurred in Russia and Kazakhstan. The
Two died from acute liver failure after use of Novartis' Zolgensma, STAT says
Novartis this week began notifying physicians and payers about the deaths of two children from acute liver failure over the past few months in Russia and Kazakhstan after they were administered the ge
This Nasal Spray For Eye Disease Stock Is 'Attractive', Has Potential 160% Upside
Chardan initiated coverage on Oyster Point Pharma Inc (NASDAQ:OYST) with a Buy rating and a price target of $22.The lead product, Tyrvaya, was approved in October 2021 and generated $1.2 million in th
FDA grants regular approval to Novartis' capmatinib for metastatic NSCLC
On August 10, The FDA granted regular approval to capmatinib, marketed as Tabrecta by Novartis, for adult patients with metastatic non-small cell lung cancer, or NSCLC, whose tumors have a mutation le
Novartis AG (NYSE:NVS) Shares Purchased by Wambolt & Associates LLC
Wambolt & Associates LLC grew its stake in Novartis AG (NYSE:NVS – Get Rating) by 4.7% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 16,315 shares of the c
Deciphera's Cancer Drug Tops Pfizer's Sutent On Safety Front In Gastrointestinal Cancer
The Journal of Clinical Oncology has published results from Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) INTRIGUE Phase 3 study of Qinlock (ripretinib) for advanced gastrointestinal stromal tumor (GIST
CIBC Asset Management Inc Purchases Shares of 5,711 Novartis AG (NYSE:NVS)
CIBC Asset Management Inc purchased a new position in shares of Novartis AG (NYSE:NVS – Get Rating) in the 1st quarter, according to the company in its most recent disclosure with the Securities and
Loading...